883 results on '"Sartore-Bianchi, Andrea"'
Search Results
2. Multimodal treatment with curative intent in a germline BRCA2 mutant metastatic ampullary adenocarcinoma: a case report
3. ALK Inhibitors in Patients With ALK Fusion–Positive GI Cancers: An International Data Set and a Molecular Case Series
4. The role of anti-EGFR rechallenge in metastatic colorectal cancer, from available data to future developments: A systematic review
5. Oncologic Emergencies in Patients Undergoing Major Surgery
6. Tolerance to colibactin correlates with homologous recombination proficiency and resistance to irinotecan in colorectal cancer cells
7. Targeting HER2 heterogeneity in breast and gastrointestinal cancers
8. Ongoing Clinical Trials and Future Research Scenarios of Circulating Tumor DNA for the Treatment of Metastatic Colorectal Cancer
9. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
10. Delphi Initiative for Early-Onset Colorectal Cancer (DIRECt) International Management Guidelines
11. Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?
12. Demystifying BRAF Mutation Status in Colorectal Liver Metastases: A Multi-institutional, Collaborative Approach to 6 Open Clinical Questions
13. The predictive role of ERBB2 point mutations in metastatic colorectal cancer: A systematic review
14. Liquid biopsies to monitor and direct cancer treatment in colorectal cancer
15. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial
16. LINE1 are spliced in non-canonical transcript variants to regulate T cell quiescence and exhaustion
17. Relationships Between Köhne Category/Baseline Tumor Load and Early Tumor Shrinkage, Depth of Response, and Outcomes in Metastatic Colorectal Cancer
18. Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer
19. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
20. Personalized therapeutic strategies in HER2-driven gastric cancer
21. Clonally expanded EOMES+ Tr1-like cells in primary and metastatic tumors are associated with disease progression
22. The challenge of molecular selection in liver-limited metastatic colorectal cancer for surgical resection: a systematic review and meta-analysis in the context of current and future approaches.
23. Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer
24. Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA
25. Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial
26. Clinicopathological characterisation ofMTAPalterations in gastrointestinal cancers
27. The challenge of molecular selection in liver-limited metastatic colorectal cancer for surgical resection: a systematic review in the context of current and future approaches
28. Chemotherapy-induced myasthenic crisis in thymoma treated with primary chemotherapy with curative intent on mechanical ventilation: a case report and review of the literature
29. The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials
30. Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer
31. Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients
32. What to do after immune-checkpoint inhibitors failure in advanced non-small cell lung cancer: an expert opinion and review
33. Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case
34. The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer
35. Empowering Clinical Decision Making in Oligometastatic Colorectal Cancer: The Potential Role of Drug Screening of Patient-Derived Organoids
36. Supplementary Data from Immune Checkpoint Inhibitors and the Exposome: Host-Extrinsic Factors Determine Response, Survival, and Toxicity
37. Data from Immune Checkpoint Inhibitors and the Exposome: Host-Extrinsic Factors Determine Response, Survival, and Toxicity
38. Total neoadjuvant treatment without surgery for locally advanced rectal cancer: Prospective study to assess tumor response, circulating genetic, and epigenetic biomarkers, and stromal transcriptome to interpret clinical outcome (NO-CUT trial).
39. Improving Outcome of Selected Patients With Non-Resectable Hepatic Metastases From Colorectal Cancer With Liver Transplantation: A Prospective Parallel Trial (COLT trial)
40. Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients
41. Impact of inter-reader contouring variability on textural radiomics of colorectal liver metastases
42. Immune Checkpoint Inhibitors and the Exposome: Host-Extrinsic Factors Determine Response, Survival, and Toxicity
43. Figure S3 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
44. Supplementary Table S1 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
45. Supplementary Methods from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
46. Data from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
47. BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
48. Data from Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients
49. Supplementary Figure 1 from Combined Low Densities of FoxP3+ and CD3+ Tumor-Infiltrating Lymphocytes Identify Stage II Colorectal Cancer at High Risk of Progression
50. Supplementary Table 1 from Combined Low Densities of FoxP3+ and CD3+ Tumor-Infiltrating Lymphocytes Identify Stage II Colorectal Cancer at High Risk of Progression
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.